
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
Kami Maddocks, MD, reviews the case of a 74-year-old man with relapsed/refractory follicular lymphoma and discusses current treatment options.
Case: A 74-Year-Old Man With Relapsed/Refractory Follicular Lymphoma
Initial presentation
Clinical Workup
Treatment
